Table 1 Demographic characteristics of COVID-19 and Non COVID-19
Before PSM | After PSM | |||||
|---|---|---|---|---|---|---|
COVID-19 N = 2781 | Non-COVID-19 N = 18,475 | SMD | COVID-19 N = 2776 | Non-COVID-19 N = 2776 | SMD | |
Age | 63.17 ± 16.18 | 62.05 ± 17.91 | 0.066 | 63.16 ± 16.19 | 63.63 ± 16.76 | 0.028 |
Sex | ||||||
Female | 1034 (37.18) | 6915 (37.43) | 0.005 | 1032 (37.18) | 1028 (37.03) | 0.003 |
Male | 1736 (62.42) | 11,368 (61.53) | 0.018 | 1733 (62.43) | 1737 (62.57) | 0.003 |
Unknown Gender | 11 (0.40) | 192 (1.04) | 0.076 | 11 (0.40) | 11 (0.40) | < 0.001 |
Race | ||||||
White | 1636 (58.83) | 11,222 (60.74) | 0.039 | 1633 (58.83) | 1639 (59.04) | 0.004 |
Black or African American | 577 (20.75) | 3694 (20.00) | 0.019 | 577 (20.79) | 578 (20.82) | 0.001 |
Asian | 165 (5.93) | 1100 (5.95) | 0.001 | 165 (5.94) | 189 (6.81) | 0.035 |
American Indian or Alaska Native | 15 (0.54) | 59 (0.32) | 0.034 | 14 (0.50) | 14 (0.50) | < 0.001 |
Native Hawaiian or Other Pacific Islander | 62 (2.23) | 414 (2.24) | 0.001 | 62 (2.23) | 56 (2.02) | 0.015 |
Other Race | 149 (5.36) | 683 (3.70) | 0.080 | 148 (5.33) | 130 (4.68) | 0.030 |
Unknown Race | 177 (6.37) | 1303 (7.05) | 0.028 | 177 (6.38) | 170 (6.12) | 0.010 |
BMI | 30.39 ± 8.71 | 28.54 ± 8.08 | 0.221 | 30.40 ± 8.71 | 28.95 ± 7.90 | 0.175 |
Medical utility | ||||||
Ambulatory | 1455 (52.32) | 10,070 (54.51) | 0.044 | 1452 (52.31) | 1433 (51.62) | 0.014 |
Emergency | 1125 (40.45) | 7281 (39.41) | 0.021 | 1122 (40.42) | 996 (35.88) | 0.094 |
Inpatient Encounter | 840 (30.21) | 5890 (31.88) | 0.036 | 838 (30.19) | 764 (27.52) | 0.059 |
Comorbidities | ||||||
Hypertensive diseases | 1173 (42.18) | 7836 (42.41) | 0.005 | 1171 (42.18) | 1097 (39.52) | 0.054 |
Disorders of lipoprotein metabolism and other lipidemias | 862 (31.00) | 5761 (31.18) | 0.004 | 861 (31.02) | 809 (29.14) | 0.041 |
Ischemic heart diseases | 611 (21.97) | 4292 (23.23) | 0.030 | 611 (22.01) | 576 (20.75) | 0.031 |
Chronic kidney disease | 614 (22.08) | 3814 (20.64) | 0.035 | 614 (22.12) | 572 (20.61) | 0.037 |
Overweight and obesity | 383 (13.77) | 2106 (11.40) | 0.072 | 381 (13.73) | 342 (12.32) | 0.042 |
Cerebrovascular diseases | 216 (7.77) | 1723 (9.33) | 0.056 | 216 (7.78) | 217 (7.82) | 0.001 |
Diseases of liver | 187 (6.72) | 1427 (7.72) | 0.039 | 187 (6.74) | 177 (6.38) | 0.015 |
Chronic obstructive pulmonary disease | 294 (10.57) | 2339 (12.66) | 0.065 | 294 (10.59) | 273 (9.83) | 0.025 |
Malignant neoplasms of lip, oral cavity and pharynx | 11 (0.40) | 116 (0.63) | 0.033 | 11 (0.40) | 12 (0.43) | 0.006 |
Malignant neoplasms of digestive organs | 28 (1.01) | 378 (2.05) | 0.085 | 28 (1.01) | 33 (1.19) | 0.017 |
Malignant neoplasms of respiratory and intrathoracic organs | 42 (1.51) | 363 (1.97) | 0.035 | 42 (1.51) | 43 (1.55) | 0.003 |
Malignant neoplasms of bone and articular cartilage | 0 (0.00) | 21 (0.11) | 0.048 | 0 (0.00) | 10 (0.36) | 0.085 |
Melanoma and other malignant neoplasms of skin | 25 (0.90) | 196 (1.06) | 0.016 | 25 (0.90) | 36 (1.30) | 0.038 |
Malignant neoplasms of mesothelial and soft tissue | 10 (0.36) | 67 (0.36) | 0.001 | 10 (0.36) | 10 (0.36) | < 0.001 |
Malignant neoplasms of breast | 20 (0.72) | 188 (1.02) | 0.032 | 20 (0.72) | 15 (0.54) | 0.023 |
Malignant neoplasms of female genital organs | 12 (0.43) | 101 (0.55) | 0.017 | 12 (0.43) | 10 (0.36) | 0.011 |
Malignant neoplasms of male genital organs | 34 (1.22) | 295 (1.60) | 0.032 | 34 (1.23) | 44 (1.59) | 0.031 |
Malignant neoplasms of urinary tract | 27 (0.97) | 166 (0.90) | 0.008 | 27 (0.97) | 20 (0.72) | 0.028 |
Malignant neoplasms of eye, brain and other parts of central nervous system | 0 (0.00) | 44 (0.24) | 0.069 | 0 (0.00) | 0 (0.00) | < 0.001 |
Malignant neoplasms of thyroid and other endocrine glands | 10 (0.36) | 43 (0.23) | 0.023 | 10 (0.36) | 10 (0.36) | < 0.001 |
Malignant neoplasms of ill-defined, other secondary and unspecified sites | 65 (2.34) | 707 (3.83) | 0.086 | 65 (2.34) | 53 (1.91) | 0.030 |
Malignant neuroendocrine tumors | 10 (0.36) | 33 (0.18) | 0.035 | 10 (0.36) | 10 (0.36) | < 0.001 |
Secondary neuroendocrine tumors | 0 (0.00) | 13 (0.07) | 0.038 | 0 (0.00) | 10 (0.36) | 0.085 |
Malignant neoplasms of lymphoid, hematopoietic and related tissue | 76 (2.73) | 338 (1.83) | 0.061 | 73 (2.63) | 61 (2.20) | 0.028 |